Has your health system prepared for HRSA’s forthcoming 340B Rebate Model Pilot Program, scheduled to begin January 1, 2026? We have. At the bottom of this post, you’ll find a detailed overview of exactly how our 340B team has prepared to help the 340B health systems we serve — including a short-term loan program we’ll … Read More
Since 2019, VytlOne has supported the 340B programs of more than 100 health systems and health centers. We’ve published dozens of posts exploring 340B topics and trends — major, minor and developing. Recently, we were asked by a reader to produce a post offering our thoughts on, and predictions for, the program’s future. If there … Read More
How can this unprecedented manufacturer restriction generate the company, OR patients, a net benefit? It would not be an exaggeration to say that Bausch Health (BHC) sent shockwaves through much of the healthcare industry in declaring its intention to cease participation in what it deemed two “optional” Federal drug pricing programs — the Medicaid Drug … Read More
How to make Pharmacy “The Easy Part” of the patient experience. Anyone who’s ever been a hospital patient, or patient caregiver, knows that the mental strain of a serious illness can often match the negative impact of the physical trauma. Particularly when an illness is chronic and/or long-term, the stress involved in managing the details … Read More
Since late 2019, VytlOne has supported the 340B programs of 33 health systems and 38 health centers. Altogether, we’ve generated nearly $1 billion in pharmacy-related savings for our clients. We analyze 340B program-savings potential for dozens of prospective clients every year. And not once have we ever served, or encountered, a health system capable of … Read More
Before we begin, we’re going to be honest with you. A significant component of VytlOne’s business is guiding 340B health systems through the process of building, accrediting, funding, launching and managing on-campus specialty pharmacies. Many times in this space, we’ve maintained that every 340B hospital should consider owning a specialty pharmacy. We’re currently in the … Read More
Fair Warning: If you ever dismissively ask that question (above) of someone who’s led the planning and launch of a 340B hospital’s specialty pharmacy, and did it with no outside support, there’s a good chance you’ll get punched. Yes, it’s that difficult. POST OUTLINE Why is it so hard to build a 340B specialty … Read More
The evolving legal and legislative landscape surrounding the 340B Drug Pricing Program has significant implications for hospitals’ specialty pharmacies. Here’s a breakdown of the new developments and their likely impacts: Recent 340B changes and their impact on specialty pharmacies 1. 340B contract pharmacy restrictions Drug manufacturers have increasingly restricted the use of contract pharmacies, especially … Read More
Maximizing pharmacy’s role in your hospital’s revenue cycle The 340B landscape continues to evolve rapidly, with ongoing manufacturer restrictions, new compliance hurdles, and increasing financial pressures on covered entities. The average 340B-eligible hospital loses a substantial amount of money due to drug manufacturer restrictions on the program. Recent estimates indicate that hospitals and clinics collectively … Read More
How your health system can leverage visibility, your PBM and your pharmacies to achieve your financial and clinical goals. The systemic problem: Overview The U.S. prescription drug market is a textbook case of waste and inefficiency — one that, in recent years, has disproportionately benefited a handful powerful corporations at the expense of providers, … Read More
